Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 1,63 MB, PDF-dokument

  • Rajiv Agarwal
  • Luis M Ruilope
  • Gema Ruiz-Hurtado
  • Hermann Haller
  • Roland E Schmieder
  • Stefan D Anker
  • Gerasimos Filippatos
  • Bertram Pitt
  • Rossing, Peter
  • Marc Lambelet
  • Christina Nowack
  • Peter Kolkhof
  • Amer Joseph
  • George L Bakris

Objective: Finerenone is a selective nonsteroidal mineralocorticoid receptor antagonist with a short half-life. Its effects on cardiorenal outcomes were thought to be mediated primarily via nonhemodynamic pathways, but office blood pressure (BP) measurements were insufficient to fully assess hemodynamic effects. This analysis assessed the effects of finerenone on 24-h ambulatory BP in patients with chronic kidney disease and type 2 diabetes. Methods: ARTS-DN (NCT01874431) was a phase 2b trial that randomized 823 patients with type 2 diabetes and chronic kidney disease, with urine albumin-to-creatinine ratio ≥30 mg/g and estimated glomerular filtration rate of 30–90ml/min per 1.73m2 to placebo or finerenone (1.25–20mg once daily in the morning) administered over 90days. Ambulatory BP monitoring (ABPM) over 24h was performed in a subset of 240 patients at screening, Day 60, and Day 90. Results: Placebo-adjusted change in 24-h ABPM systolic BP (SBP) at Day 90 was –8.3 mmHg (95% confidence interval [CI], –16.6 to 0.1) for finerenone 10mg (n=27), –11.2 mmHg (95% CI, –18.8 to –3.6) for finerenone 15mg (n=34), and –9.9mmHg (95% CI, –17.7 to –2.0) for finerenone 20mg (n=31). Mean daytime and nighttime SBP recordings were similarly reduced and finerenone did not increase the incidence of SBP dipping. Finerenone produced a persistent reduction in SBP over the entire 24-h interval. Conclusions: Finerenone reduced 24-h, daytime, and night-time SBP. Despite a short half-life, changes in BP were persistent over 24h with once-daily dosing in the morning.

TidsskriftJournal of Hypertension
Udgave nummer2
Sider (fra-til)295-302
Antal sider8
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Sources of funding: The ARTS-DN trial was conducted and funded by Bayer AG. The funder participated in study design, data collection, data analysis, data interpretation, and approval of the manuscript. Analyses were conducted by the sponsor, and all authors had access to and participated in the interpretation of the data. Medical writing assistance was provided by Kate Weatherall, PhD, of Chameleon Communications International, and was funded by Bayer AG.

Publisher Copyright:
Copyright © 2022 The Author(s).

ID: 362460539